Loading...

Pfizer to invest USD350 mn in China biotech hub

 28-Jun-16, Reuters

Pfizer Inc will invest $350 million to build a biotech center in China, the latest in a series of moves by pharma industry giants to set up shop in the world's no. 2 drugs market with the aim of securing faster approvals for their products.

Pfizer to invest USD350 mn in China biotech hub (c) Reuters Andrew Kelly

Image: Reuters / Andrew Kelly

The facility in eastern Hangzhou region - Pfizer's first biotech center in Asia - is expected to be completed by 2018.

Global "Big Pharma" is increasingly looking for smart ways to tap China's healthcare market, worth around $185 billion by 2018. From investing in China facilities to acquisitions, licensing deals and joint ventures, the aim is to seek an edge in dealings with domestic regulators and government.

 Read the full article 

 Insights 

Share